Candel Therapeutics, Inc. (CADL) Stock Score, Valuation & Financial Research
Candel Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.
Quick answer for CADL
Candel Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 9.87. These figures are a research snapshot, not a buy or sell recommendation.
What Candel Therapeutics, Inc. does
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Company business and revenue
Research reporting period: 2025-12-31. A research update is not a new financial filing.
How the company makes money
Candel Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of viral immunotherapies, and it relies on capital raises and potential future licensing or collaboration agreements to fund its operations.
Products and services
- The company develops multimodal biological immunotherapies, including viral immunotherapy candidates such as CAN-2409 and linoserpaturev, designed to induce systemic anti-tumor immune responses.
Suppliers, materials and equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are not disclosed. Source
Business relationships and partnerships
- Mass General Brigham — The company maintains a license agreement for the development of linoserpaturev. Source
Business strengths to evaluate
- Proprietary viral immunotherapy platform technology Source
Business risks and research considerations
- History of operating losses and expectation of future losses Source
- Dependence on third-party manufacturers for clinical supply Source
- Uncertainty regarding clinical trial success and regulatory approval Source
Sources: Company research source
Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.
CADL financial snapshot
Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.
- Wall Street Score:
- Not currently available
- Stored price:
- USD 9.87
- Market capitalization:
- 723.18M (currency not supplied)
- Revenue:
- USD 0.00
- Net income:
- USD -88.53M
- Free cash flow:
- USD -38.9M
- Cash:
- USD 201.57M
- Total debt:
- USD 49.52M
- EPS:
- USD -1.41
What stands out
- Free cash flow is USD -38.9M, negative for the stored period.
- The balance sheet shows USD 201.57M of cash versus USD 49.52M of total debt, an excess of cash over debt on these two reported measures.
- The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.
Company-specific financial comparisons
The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.
- Cash exceeds debt by USD 152.05M using the stored balance-sheet values. This does not include other obligations or restricted cash.
Questions worth answering for CADL
Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.
- How long can CADL fund negative free cash flow using its current cash position before it may need more debt or new shares?
- How is CADL likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- What specifically needs to improve for CADL to reach sustainable profitability?
- What does the current fundamental change risk warning mean for the reliability or interpretation of CADL's score?
What the numbers mean
A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.
A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-10-01.
Research-input completeness: 73% of the scoring inputs required for this public page are currently available.
How to research CADL
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.